Introduction
============

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and disability worldwide and one of the leading causes of mortality in the USA and Europe.[@b1-copd-9-203]--[@b3-copd-9-203] COPD prevalence, together with COPD morbidity and mortality, varies not only across countries but also across different groups within the same country.[@b4-copd-9-203] The BOLD study (Burden of Obstructive Lung Disease; a population-based prevalence survey of noninstitutionalized adults over 40 years of age) has shown that the prevalence of COPD in females was 8.5%, although there was significant variation among different areas.[@b5-copd-9-203] Previous studies in northern Greece showed that COPD prevalence ranged between 2.5% in women aged 21--80 years and increased with age,[@b6-copd-9-203] reaching 4.8% in female smokers aged above 35 years old.[@b7-copd-9-203] Furthermore, in these studies COPD prevalence ratio ranged from 2.42 to 3.28 between men and women.[@b6-copd-9-203],[@b7-copd-9-203] When health care use was examined, visits due to COPD in primary care settings reached 451.9/10,000 residents among men but only 269.4/10,000 residents (ie, 1.68 times lower) in women.[@b8-copd-9-203]

In the US, the prevalence and mortality of COPD in females appears to be increasing,[@b9-copd-9-203] while in Greece a large number of patients remain undiagnosed.[@b10-copd-9-203] The lower percentage of women with COPD in Greece is probably related to the low smoking habit of Greek women in rural areas, as it has been recently reported that 96% of women above the age of 60 in northern Greece are nonsmokers.[@b11-copd-9-203]

Recent studies have shown that disease manifestations differ between men and women;[@b12-copd-9-203],[@b13-copd-9-203] women tend to develop COPD at a younger age and have a shorter smoking history compared to men suffering from the disease of the same stage.[@b13-copd-9-203] Female patients with COPD seem to have fewer comorbidities, better arterial blood gases, lower BMI, a lower exercise capacity, a greater degree of dyspnea, and a lower health-related quality of life compared to male patients of the same COPD stage.[@b12-copd-9-203] These differences in COPD manifestations in women could possibly be the result of differences in tobacco susceptibility caused by a genetic susceptibility.[@b14-copd-9-203] According to the aforementioned observations, female COPD patients might require earlier diagnosis, closer disease monitoring, and more intensive therapeutic interventions compared to male COPD patients. The understanding of sex differences in COPD in our country might be helpful for the better design of a diagnostic and therapeutic strategy.

The aim of the present study was to evaluate the burden of COPD among females in Greece in a large sample of COPD patients through a nationwide cross-sectional survey of respiratory medicine physicians and to explore sex differences regarding functional characteristics, smoking habit, and exacerbation frequency.

Methods
=======

Study design
------------

In order to estimate the nationwide rate of newly diagnosed cases, it was essential to take into account that COPD diagnosis and treatment could be performed either in hospitals or in the offices of private practitioners (mainly respiratory medicine physicians). The present study followed a nationwide sampling approach of respiratory medicine physicians. First, we estimated the expected incidence (new) and prevalence of COPD cases in Greece, in each prefecture (52 administrative areas covering the whole country) and in total. We used the range of various comparative and area-specific estimations of COPD incidence (and prevalence) ratios stratified per age group and sex published in the international literature,[@b15-copd-9-203],[@b16-copd-9-203] plus data on population age and sex strata in every prefecture from the Hellenic Statistical Authority.[@b17-copd-9-203] Next, in order to estimate the expected incidence of COPD cases per physician in each prefecture, we used data on the number of Greek pulmonologists per prefecture provided by the Hellenic Thoracic Society.[@b18-copd-9-203] Based on these ratios (ie, the expected COPD cases per physician in each prefecture) we created a frame of three different sampling zones by assigning in each zone prefectures with proximate ratios. These zones included the "tertiary hospital zone", areas with very large hospitals, very high density of respiratory medicine physicians, and low ratios of expected COPD cases per physician; the "intermediate zone", areas with large respiratory medicine departments and many private practitioners; and a third zone which included all remaining prefectures -- areas with mostly aging rural populations and few respiratory medicine physicians.

To cope with the (unknown) variation arising from possible differences among hospital respiratory medicine departments (ie, size, organizational factors, and other differences), we decided to include as many departments as feasible. Respiratory medicine physicians from 45 respiratory medicine departments throughout Greece participated. Both a convenience and judgment sampling (quota sampling) was employed. The respiratory medicine departments of the participating hospitals are shown in [Table 1](#t1-copd-9-203){ref-type="table"}, and the areas of the country from which physicians have collected data are shown in [Figure 1](#f1-copd-9-203){ref-type="fig"}.

Respiratory care in the health system in Greece is organized in three levels: 1) general practitioners and private practice doctors offering mainly primary care services; 2) general hospitals offering secondary care, such as treatment in the emergency department and inpatient care; and 3) tertiary hospitals, usually university hospitals, which provide more specialized care, such as intermediate care units and intensive care units. For the needs of the present study, respiratory medicine physicians from all levels were recruited. All physicians were sampled at one time point. Study participants were COPD patients from all over the country who visited chest physicians either routinely or because of symptom deterioration.

All data collection was performed over a 6-month period (October to March 2011). In total, 218 respiratory medicine physicians expressed interest in participating (134 private practitioners and 84 hospital doctors). At the end of the study, data were provided from 199 respiratory medicine physicians (124 private practitioners and 75 hospital doctors; response rate 92.5% and 89.3%, respectively) ([Figure 2](#f2-copd-9-203){ref-type="fig"}).

During the 6-month study period, each respiratory medicine physician was asked to register all consecutive COPD patients visiting their clinic/office. Inclusion criteria included age greater than 40 years, a diagnosis of COPD established according to the GOLD (Global initiative for chronic Obstructive Lung Disease) criteria,[@b4-copd-9-203] residence in the prefecture of their practice, ability of the patient to provide data about their disease history, and consent of the patient to participate in the study. Patients who refused to participate, who had participated in a similar study during the last month, or had a history of asthma were excluded.

Each physician completed a questionnaire which included the patients' demographics (ie, age, sex, occupation, place of residence, body mass index \[BMI\]), smoking status, time since diagnosis of COPD, current medication use (type, dose, and frequency), comorbidities, frequency of exacerbations, and hospitalizations for a COPD exacerbation and/or intensive care unit (ICU) admissions. The term "newly diagnosed COPD" was used for cases that were first diagnosed during the study period (ie, patients who were referred for the first time during the study period to a physician participating in the study and in whom the diagnosis was established with spirometry). Type I and Type II respiratory failure (ie, the presence of hypoxia, or hypoxia and hypercapnia, respectively) was also recorded. Sick leave days due to COPD and early retirement due to the disease were also recorded. Ex-smokers were defined as smokers who had quit smoking for at least 12 months. Smoking history was measured by pack-years, defined as the number of cigarettes smoked per day divided by 20 and multiplied by the number of years of smoking. According to their smoking history, subjects were classified into three categories: never-smokers, ex-smokers, and current smokers. Compliance with therapy was assessed by physicians according to the monthly prescription of medication and the patients' and/or relatives' reporting on the regular use of the prescribed medication.

Pre- and postbronchodilation spirometry measurements were performed in all study subjects and forced expiratory volume in 1 second (FEV~1~), forced vital capacity (FVC), and FEV~1~/FVC ratio were recorded. Postbronchodilator values (ie, 30 minutes after the administration of 400 μg salbutamol with a spacer) were used for the evaluation of COPD severity, according to GOLD guidelines (Stage I: mild COPD, FEV~1~ \>80.0% predicted; Stage II: moderate COPD, 50.0%≤ FEV~1~ \<80.0% predicted; Stage III: severe COPD, 30.0%≤ FEV~1~ \<50.0%; Stage IV: very severe COPD, FEV~1~ \<30.0%, or FEV~1~ \<50.0% predicted with respiratory failure).[@b4-copd-9-203]

The study protocol was approved by the ethics committee of all hospitals where the study was performed, as well as the National Organization for Medicines. All subjects provided written informed consent.

Statistical methods and analysis
--------------------------------

For the description of the qualitative variables, absolute (number of observations) and relative frequencies (percentages) were used. The description of the quantitative variables was based on the calculation of the median and the interquartile range (IQR). The association of the qualitative variables with sex was clarified using Pearson's χ^2^ test. The statistical evaluation of the differentiation of the quantitative variables according to sex was based on the application of the nonparametric Mann--Whitney *U* test.

For the investigation of the effect of sex (adjusted for the other factors) on hospitalization in ICU, and on retirement due to COPD, logistic regression was applied. For the analysis of the number of exacerbations in the preceding year, hospitalizations (per year), days of hospitalization per exacerbation, days of hospitalization in ICU, days of absence from work (per year) and number of outpatient visits (per year), zero-inflated Poisson regressions were applied. The use of zero-inflated Poisson regression instead of the familiar Poisson regression is justified by the high number of zero values in our data.[@b19-copd-9-203] This choice was documented using a Vuong statistical test.[@b19-copd-9-203]

Results
=======

Study participants
------------------

In total, 199 respiratory medicine physicians provided data from 6,125 COPD patients. There were no differences regarding the location of practice, training, or patient population between physicians who provided data and those who did not. Demographic and clinical characteristics of the study subjects are shown in [Table 2](#t2-copd-9-203){ref-type="table"}. Female patients represented 28.7% of the study participants and were on average 5 years younger than male COPD patients (median 64 versus \[vs\] 69 for female and male COPD patients, respectively, *P*\<0.001). Female COPD patients seemed to have lower BMI: 27.3 kg/m^2^ vs 27.7 kg/m^2^ for female and male COPD patients, respectively (*P*=0.036), although this difference might not have clinical significance.

Only 4.6% of the COPD patients who participated in the study were never smokers. Never smokers accounted for 9.4% among female patients, compared to 2.7% among male patients (*P*\<0.001). Male patients had more pack-years compared to female patients (median \[IQR\]: 52 \[36--75\] vs 35 \[22--50\]) for male and female patients, respectively, *P*\<0.001). Finally, among women, current smokers were younger compared to ex-smokers and never smokers (62.3±0.2 years vs 69.0±0.4 years, *P*\<0.001), and never smokers were older compared to current smokers and ex-smokers (69.5±0.5 years vs 62.9±0.2 years, *P*\<0.001).

COPD diagnosis and severity
---------------------------

Newly diagnosed COPD cases were more prominent in females than in males (20.2% vs 17.1%, *P*=0.005). Furthermore, female patients were found to have a more recent diagnosis of COPD compared to male patients (median \[IQR\]: 8 \[4--12\] years vs 10 \[5--15\] years) for females and males, respectively (*P*\<0.001).

COPD severity (defined by the GOLD COPD stage)[@b4-copd-9-203] was significantly related to sex; 24.6% of females were diagnosed as COPD GOLD Stage I compared to 17.2% of males, while 13.3% of females were diagnosed as COPD GOLD Stage IV compared to 22.1% of males. Severe and very severe disease (GOLD Stages III and IV) was more prominent in male patients (47.9% vs 38.5; *P*\<0.001 for male and female patients, respectively).

COPD exacerbations and hospital admissions
------------------------------------------

A median of two exacerbations during the preceding year was reported in our study, with no difference between males and females (*P*=0.826). Hospital admissions also did not differ significantly between sexes (*P*=0.116).

The odds of hospitalization in the ICU tended to be lower in female COPD patients by 35.6% compared to males (odds ratio \[OR\] 0.644; 95% confidence interval \[CI\]: 0.468--0.887, *P*=0.007). However, multivariate analysis after adjustment for age, occupation, BMI, duration of COPD, COPD severity, smoking status, compliance to therapy, and comorbid conditions did not reveal any difference between sexes (OR 0.614; 95% CI: 0.335--1.0.69, *P*=0.082).

Comorbidities
-------------

The majority of COPD patients who participated in the study reported at least one comorbid condition ([Table 3](#t3-copd-9-203){ref-type="table"}). The most common comorbidities were arterial hypertension, diabetes mellitus, congestive heart failure, gastroesophageal reflux, bronchiectasis, and sleep apnea syndrome. Comorbid conditions were more prevalent in men, with the exception of gastroesophageal reflux, which was more prevalent in women (14.6% vs 17.1% for men and women, respectively, *P*=0.013). It is worth mentioning that 16.4% of men and 13.6% of women reported at least four comorbidities, including COPD.

Heath care utilization
======================

Outpatient care
---------------

Outpatient care during the preceding year included various tests such as chest X-ray, spirometry, computed tomography of the chest, measurement of arterial blood gases, and bronchoscopy ([Table 4](#t4-copd-9-203){ref-type="table"}). No particular sex difference was observed in diagnostic tests performed on outpatient COPD patients during the preceding year, with the exception of arterial blood gases analysis, which was performed more often in male patients ([Table 4](#t4-copd-9-203){ref-type="table"}).

In univariate analysis ([Table 5](#t5-copd-9-203){ref-type="table"}), patients aged 61--75 years and 76 years and older seemed to have a higher expected number of outpatient visits per year, by 11.3% and 13.7%, respectively, compared to younger patients. However, this was not confirmed in the multivariate analysis. Female COPD patients had a higher expected number of outpatient visits per year by 8.9% compared to males (univariate analysis, *P*\<0.001), with a slightly lower but still significant difference in the multivariate analysis. Other significant predictors of increased outpatient health care utilization were severe and very severe disease (GOLD Stages III and IV), multiple comorbid diseases, previous established COPD diagnosis, and good compliance to COPD pharmacological treatment ([Table 5](#t5-copd-9-203){ref-type="table"}). In contrast, newly diagnosed cases, and patients with poor compliance to COPD treatment provided a decreased expected number of outpatient visits ([Table 5](#t5-copd-9-203){ref-type="table"}).

Absence from work due to COPD
-----------------------------

Results from the comparison between sexes on the number of sick-leave days, excluding patients older than 65 years (ie, mostly pensioners) and homemakers revealed that females had a lower number of days of absence from work due to COPD per year by 19.0% (*P*\<0.001) compared to males, after adjusting for the covariates of the model ([Table 6](#t6-copd-9-203){ref-type="table"}). During the preceding year, the majority of COPD patients (83.7%) did not take sick leave due to COPD. Among those with sickness absence, females took mainly short sick leaves (up to 6 days), 39% of females compared to 30.1% for males; while 26.2% of male patients reported more than 20 days of sick leave during the preceding year compared to 15.6% of females.

Results from the univariate analysis of days of absence from work due to COPD per year for patients aged \<65 years are listed in [Table 6](#t6-copd-9-203){ref-type="table"}. Females had a lower number of sick leave days per year by 28.2% (*P*\<0.001) compared to males. Obese patients and patients who omitted medication had an increased number of sick leave days by 47.1% (*P*\<0.001), and 5.5% (*P*=0.043), respectively. Patients with higher comorbidity, more severe COPD (GOLD stage), and longer disease duration had a two- to threefold increase in the number of sick leave days ([Table 6](#t6-copd-9-203){ref-type="table"}).

Furthermore, patients with COPD GOLD Stage II, III, and IV had a higher number of days of absence from work due to COPD per year by 11.8% (*P*=0.032), 59.7% (*P*\<0.001), and 90.5% (*P*\<0.001), respectively, compared to patients with mild COPD (GOLD 1), after adjusting for the covariates of the model. Patients with good compliance to therapy (as expressed by the intake of medication) as well as patients with newly diagnosed COPD had fewer expected days of absence from work due to COPD per year by 44.1% (*P*\<0.001) and 11.9% (*P*=0.024), respectively, after adjusting for the covariates of the model. Patients with three and four or more comorbidities had increased expected number of days of absence from work (incidence rate ratio \[IRR\] \[95% CI\], 1.494 \[1.321--1.689\], *P*\<0.001 and 2.355 \[2.102--2.639\], *P*\<0.001, respectively) compared to patients with no comorbidities, after adjusting for the covariates of the model ([Table 6](#t6-copd-9-203){ref-type="table"}).

Discussion
==========

In the Greek Obstructive Lung Disease Epidemiology and health ecoNomics (GOLDEN) study GOLDEN cross-sectional study, more than 6,000 COPD patients provided a plethora of useful data on various aspects of COPD in Greece. In our study population, female patients have a shorter smoking history and less severe disease (according to the GOLD classification) compared to male COPD patients. Furthermore, although female patients with COPD in Greece report fewer comorbid conditions and they are less likely to be admitted to the hospital compared to males, they have reported significantly more outpatient visits. Finally, female COPD patients in Greece have fewer sick leave days due to COPD compared to male COPD patients.

The well-known impact of smoking as the main cause of COPD[@b4-copd-9-203] is also shown in our study, since only 4.6% of our study participants were never smokers. Indoor pollution is also a common cause for COPD development; causes such as passive smoking as well as the use of biomass (wood, crop residues, twigs, shrubs, dried dung, and charcoal) and coal, collectively known as solid fuels, which are used to meet basic domestic energy demands for cooking, lighting, and heating, have been associated with COPD in nonsmokers.[@b20-copd-9-203] Among COPD patients, never smokers were significantly more frequently women than men. This is in agreement with the Greek culture, since the great majority of older females are more likely to be never smokers. Interestingly, a high number of women in Greece are homemakers, responsible for the cooking and heating, being thus exposed to biomass fuels. These facts in combination with their possible exposure to passive smoking might explain the fact that they are the majority of the never smokers among Greek COPD patients.

Our study results are in agreement with previous observations reporting that female COPD patients are younger and have a lower BMI compared to male patients of the same COPD stage.[@b13-copd-9-203] Interestingly, in our population, female patients were reported to have more outpatient visits, although they did not have more hospital admissions or more severe disease. This is probably related to a social--sex characteristic (at least in Greece) which makes it more likely for females to seek medical care earlier than males[@b21-copd-9-203] and therefore be diagnosed in a less severe COPD stage.

Although previous studies have shown that comorbid conditions were highly prevalent in women,[@b12-copd-9-203] in our study, comorbid conditions such as hypertension and heart failure were more prevalent in men. This fact could be possibly explained by the age difference between male and female patients, but also by the fact that male COPD patients had more severe airflow limitation, also found to be related to increased prevalence of comorbidities.[@b22-copd-9-203] Interestingly, the only comorbid condition which was more prevalent in female patients from our study group was gastroesophageal reflux. Previous studies have shown a dose-dependent association between body mass and reflux esophagitis in women as opposed to no association among men, which is probably related to estrogen activity in obese females.[@b23-copd-9-203] The fact that a great percentage of female patients were at least overweight (median BMI 27.3 kg/m^2^, IQR 24.4--31.2) in our study probably contributes to the increased prevalence of gastroesophageal reflux.

Although female COPD patients reported more outpatient visits, multivariate analysis after adjustment for age, occupation, BMI, duration of COPD, COPD severity, smoking status, and comorbid conditions did not reveal any difference in hospitalizations and ICU admissions between sexes. Previous studies have shown that disease severity and comorbidities are related to more frequent exacerbations.[@b24-copd-9-203],[@b25-copd-9-203] However, in our study, although males had more comorbidities, they did not appear to have more hospital and ICU admissions. A study in Norway has shown that the use of outpatient services was also related to several cultural and socioeconomic characteristics and was more frequent in women over 60 years of age.[@b26-copd-9-203]

Finally, we have shown that although female COPD patients had more outpatient visits, they experienced fewer absences from work due to COPD compared to male patients. This may be due to greater sickness presenteeism among females or employment in less physically demanding jobs compared to men.

Our study has several limitations. First, even though the quota is a nonprobability (nonrandom) sampling, it was judged as not introducing any significant bias in the study. However, it is possible that this sampling method might limit the generalizability of the results. Second, there could be a possible selection bias due to the time period and seasonal variations, especially regarding COPD exacerbations. This is due to the fact that COPD exacerbations (which are related to symptoms deterioration) are more frequent during the winter season,[@b27-copd-9-203] which may lead more COPD patients to seek medical assessment. Additionally, variation could have been introduced by the fact that many patients with less severe disease might not look for medical advice or might be treated by general practitioners and internists rather than by respiratory medicine physicians. To a limited extent, recall bias for the self-reported variables is possible, although the involvement of expert physicians ensured the validity of the data collected. Finally, comorbidities were recorded according to the patients' medical history and his/her personal medical files. According to the Greek medical system, medical files contain information on diagnostic examinations and their results as well as all information on the prescribed medication for each condition diagnosed. The respiratory medicine physicians who participated in the GOLDEN study did not perform additional tests to confirm the diagnosis of a comorbid condition for the study purposes (unless necessary for the routine care of the patient); it is thus possible that in some patients, this led to an under-diagnosis of comorbid conditions.

In conclusion, the GOLDEN study has provided a wealth of information that can enhance the understanding of the possible differences between male and female Greek COPD patients. Although Greek female COPD patients present with less severe disease and have fewer comorbidities compared to Greek male patients, they remain an important part of the COPD population regarding the use of health care services in both outpatient and inpatient care.

The differences observed reveal certain cultural characteristics related to sex and disease prevalence, such as smoking history and earlier COPD diagnosis for females. It is evident that both males and females have to be informed and educated from a younger age on the deleterious effects of smoking and encouraged to attend smoking cessation programs. The fact that in Greece COPD is prevalent even in never smoker females indicates that the physicians should be sensitized for COPD diagnosis in females, even when there is no smoking history. The frequent outpatient visits and health care facilities utilization increase the cost of COPD care. Hence, COPD patients should be educated on the early identification and better management of their symptoms as well as on the identification, reporting, and management of COPD exacerbations. This could potentially reduce costs and unnecessary utilization of health care services. The differences observed between male and female COPD patients provide important information which could set the foundations for the better prevention and management of the disease in Greece.
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**Notes:** In total, 218 respiratory medicine physicians agreed to collect and provide data (134 private respiratory medicine practitioners and 84 hospital doctors). At the end of the study, data were provided from 199 respiratory medicine physicians (124 private practitioners and 75 hospital doctors; response rate 92.5% and 89.3%, respectively).\
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###### 

Hospitals whose respiratory medicine departments have participated in the study

  Region          Location                            Number of hospitals that participated in the study
  --------------- ----------------------------------- ----------------------------------------------------
  Thessaly        Central Greece                      2
  Athens          Central Greece (Capital)            7
  Chios           Aegean Sea (Island)                 1
  Crete           South Frontier of Greece (Island)   4
  Ionian Region   Ionian Sea                          2
  Euboea          Central Greece                      1
  Lamia           Central Greece                      1
  Ioannina        West Greece                         2
  Peloponnese     Southern Greece                     2
  Thessaloniki    Northern Greece                     3
  Macedonia       Northern Greece                     3
  Thrace          Eastern Greece                      2

###### 

Demographic and clinical characteristics of the study participants

                                                                              Sex                 *P*-value           
  --------------------------------------------------------------------------- ------------------- ------------------- ---------
  Age, years                                                                  69 (60.5--73)       64 (56--73)         \<0.001
  Body mass index, kg/m^2^                                                    27.7 (25.1--30.5)   27.3 (24.4--31.2)   \<0.036
  Smoking status                                                              N=4,305             N=1,694             
   Current smokers                                                            1,982 (46.0)        887 (52.4)          \<0.001
   Ex-smokers                                                                 2,061 (47.9)        458 (27.3)          \<0.001
   Never smokers                                                              262 (6.1)           349 (20.6)          \<0.001
   Pack-years                                                                 52 (36--75)         35 (22--50)         \<0.001
  GOLD COPD stage                                                             N=4,360             N=1,754             \<0.001
   I                                                                          749 (17.2)          432 (24.6)          
   II                                                                         1,521 (34.9)        646 (36.8)          
   III                                                                        1,125 (25.8)        442 (25.2)          
   IV                                                                         965 (22.1)          234 (13.3)          
  Newly diagnosed cases                                                       720 (17.1)          344 (20.2)          0.005
  Therapy compliance (how often someone forgets to take his/her medication)                                           0.854
   Never/almost never                                                         2,320 (54.8)        922 (53.9)          
   \<3 times a month                                                          904 (21.4)          372 (21.7)          
   1 time a week                                                              477 (11.3)          189 (11.0)          
   \>1 time a week or almost every day                                        532 (12.6)          228 (13.3)          
  Respiratory failure -- Type I                                               1,023 (23.6)        399 (22.9)          0.544
  Respiratory failure -- Type II                                              495 (11.5)          129 (7.4)           \<0.001
  Use of nebulizer                                                            1,003 (23.0)        313 (17.9)          \<0.001
  Noninvasive mechanical ventilation                                          151 (3.5)           50 (2.9)            0.222
  Number of exacerbations in the preceding year                               2.0 (0.0--3.0)      2.0 (0.0--3.0)      0.826
  Number of hospitalizations in the preceding year                            0.0 (0.0--1.0)      0.0 (0.0--1.0)      0.116
  Hospitalization in ICU                                                      186 (4.3)           49 (2.8)            0.007

**Note:** Data are presented as median (interquartile ranges) for numerical variables or as number (%) for categorical variables.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ICU, intensive care unit.

###### 

Comorbid diseases in the study participants

  ----------------------------------------------------------------------------------------------------
  \(A\) Number of comorbid diseases, COPD not included   Male\          Female\        *P*-value
                                                         N=4,367\       N=1,758\       
                                                         N (%)          N (%)          
  ------------------------------------------------------ -------------- -------------- ---------------
  0                                                      742 (17.4)     351 (20.3)     ***P*=0.015**

  1                                                      1,114 (26.1)   453 (26.2)     

  2                                                      1,012 (23.7)   418 (24.1)     

  3                                                      708 (16.6)     274 (15.8)     

  4+                                                     699 (16.4)     235 (13.6)     

                                                                                       

  **(B) Most common comorbid diseases**                  **Male**\      **Female**\    ***P*-value**
                                                         **N=4,367**\   **N=1,758**\   
                                                         **N (%)**      **N (%)**      

                                                                                       

  Arterial hypertension                                  2,514 (57.8)   865 (49.3)     \<**0.001**

  Diabetes mellitus                                      917 (21.1)     336 (19.2)     **0.094**

  Congestive heart failure                               933 (21.5)     252 (14.4)     \<**0.001**

  Gastroesophageal reflux                                634 (14.6)     300 (17.1)     **0.013**

  Bronchiectasis                                         595 (13.7)     265 (15.1)     0.146

  Cor pulmonale                                          487 (11.2)     123 (7.0)      \<**0.001**

  Latent tuberculosis                                    419 (9.6)      119 (6.8)      \<**0.001**

  Obstructive sleep apnea syndrome                       329 (7.6)      99 (5.7)       **0.008**
  ----------------------------------------------------------------------------------------------------

**Note:** Statistically significant differences between male and female patients are shown in **bold**.

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Most common diagnostic tests performed to outpatient study participants during the preceding year

  ------------------------------------------------------------------------
  Most common diagnostic tests   Male\          Female\        *P*-value
                                 N=4,367\       N=1,758\       
                                 N (%)          N (%)          
  ------------------------------ -------------- -------------- -----------
  Chest X-ray                    3,000 (72.5)   1,160 (70.4)   0.114

  Spirometry                     2,999 (72.6)   1,163 (70.7)   0.151

  Blood gases                    1,573 (38.3)   557 (34.0)     0.002

  Computed tomography            602 (14.7)     232 (14.2)     0.595

  Bronchoscopy                   154 (3.8)      55 (3.4)       0.449

  Other                          844 (20.7)     350 (21.5)     0.504
  ------------------------------------------------------------------------

###### 

Univariate and multivariate analysis of the number of outpatient visits per year (results from a zero-inflated Poisson model)

  ---------------------------------------------------------- --------------------- ----------------------- --------- -------- ---------------- ---------
                                                             Univariate analysis   Multivariate analysis                                       
  IRR                                                        95% CI                *P*-value               IRR       95% CI   *P*-value        
  Age (years)                                                                                                                                  
   ≤60[\*](#tfn5-copd-9-203){ref-type="table-fn"}            1                                                       1                         
   61--75                                                    1.113                 (1.069--1.159)          \<0.001   0.922    (0.874--0.974)   0.003
   76+                                                       1.137                 (1.085--1.192)          \<0.001   0.832    (0.779--0.889)   \<0.001
  Sex                                                                                                                                          
   Male[\*](#tfn5-copd-9-203){ref-type="table-fn"}           1                                                       1                         
   Female                                                    1.089                 (1.051--1.129)          \<0.001   1.057    (1.000--1.116)   0.049
  Body mass index                                                                                                                              
   Normal[\*](#tfn5-copd-9-203){ref-type="table-fn"}         1                                                       1                         
   Overweight                                                0.942                 (0.904--0.981)          0.004     0.898    (0.856--0.943)   \<0.001
   Obese                                                     1.109                 (1.063--1.156)          \<0.001   1.044    (0.992--1.098)   0.1
  Duration of COPD (years)                                                                                                                     
   ≤5[\*](#tfn5-copd-9-203){ref-type="table-fn"}             1                                                       1                         
   6--10                                                     1.154                 (1.101--1.209)          \<0.001   1.129    (1.070--1.191)   \<0.001
   11+                                                       1.472                 (1.408--1.539)          \<0.001   1.36     (1.289--1.435)   \<0.001
  Newly diagnosed case                                                                                                                         
   No[\*](#tfn5-copd-9-203){ref-type="table-fn"}             1                                                                                 
   Yes                                                       0.683                 (0.648--0.720)          \<0.001   1.023    (0.942--1.111)   0.588
  Severity of COPD (GOLD scale)                                                                                                                
   I[\*](#tfn5-copd-9-203){ref-type="table-fn"}              1                                                       1                         
   II                                                        0.942                 (0.892--0.995)          0.031     0.838    (0.782--0.898)   \<0.001
   III                                                       1.287                 (1.219--1.359)          \<0.001   1.021    (0.952--1.095)   0.565
   IV                                                        1.525                 (1.445--1.609)          \<0.001   1.193    (1.110--1.281)   \<0.001
  Intake of medication                                                                                                                         
   No[\*](#tfn5-copd-9-203){ref-type="table-fn"}             1                                                                                 
   Yes                                                       1.198                 (1.132--1.267)          \<0.001   0.978    (0.907--1.055)   0.570
  Medicine omission                                                                                                                            
   No[\*](#tfn5-copd-9-203){ref-type="table-fn"}             1                                                       1                         
   Yes                                                       0.887                 (0.858--0.916)          \<0.001   0.849    (0.815--0.884)   \<0.001
  Smoking                                                                                                                                      
   Never smoker[\*](#tfn5-copd-9-203){ref-type="table-fn"}   1                                                       1                         
   Ex-smokers                                                0.88                  (0.833--0.930)          \<0.001   0.861    (0.803--0.924)   \<0.001
   Light smokers (\<20 pack-years)                           0.933                 (0.860--1.012)          0.095     1.034    (0.932--1.147)   0.527
   Heavy smokers (\>20 pack-years)                           0.826                 (0.780--0.874)          \<0.001   0.904    (0.841--0.973)   0.007
  Comorbidity (number of diseases)                                                                                                             
   0[\*](#tfn5-copd-9-203){ref-type="table-fn"}              1                                                       1                         
   1                                                         1.26                  (1.178--1.348)          \<0.001   1.202    (1.110--1.300)   \<0.001
   2                                                         1.464                 (1.371--1.563)          \<0.001   1.295    (1.196--1.401)   \<0.001
   3                                                         1.79                  (1.676--1.912)          \<0.001   1.492    (1.378--1.615)   \<0.001
   4+                                                        1.919                 (1.799--2.048)          \<0.001   1.455    (1.341--1.578)   \<0.001
  ---------------------------------------------------------- --------------------- ----------------------- --------- -------- ---------------- ---------

**Note:**

Reference category.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; IRR, incidence rate ratio.

###### 

Univariate and multivariate analysis of the number of days of absence from work due to COPD per year for patients aged \<65 years whose occupation is not household and are not retired or unemployed (results from a zero-inflated Poisson model)

                                                             Univariate analysis   Multivariate analysis                                      
  ---------------------------------------------------------- --------------------- ----------------------- --------- ------- ---------------- ---------
  Sex                                                                                                                                         
   Male[\*](#tfn7-copd-9-203){ref-type="table-fn"}           1                                                       1                        
   Female                                                    0.718                 (0.676--0.763)          \<0.001   0.810   (0.753--0.871)   \<0.001
  Body mass index (kg/m^2^)                                                                                                                   
   Normal[\*](#tfn7-copd-9-203){ref-type="table-fn"}         1                                                       1                        
   Overweight                                                1.007                 (0.943--1.075)          0.841     0.839   (0.776--0.906)   \<0.001
   Obese                                                     1.471                 (1.376--1.573)          \<0.001   1.032   (0.951--1.120)   0.447
  Duration of COPD (years)                                                                                                                    
   \<5[\*](#tfn7-copd-9-203){ref-type="table-fn"}            1                                                       1                        
   6--10                                                     1.278                 (1.199--1.363)          \<0.001   1.065   (0.991--1.144)   0.089
   11+                                                       1.602                 (1.499--1.712)          \<0.001   0.980   (0.902--1.065)   0.641
  Newly diagnosed case                                                                                                                        
   No[\*](#tfn7-copd-9-203){ref-type="table-fn"}             1                                                       1                        
   Yes                                                       0.759                 (0.710--0.812)          \<0.001   0.881   (0.790--0.983)   0.024
  Severity of COPD (GOLD scale)                                                                                                               
   I[\*](#tfn7-copd-9-203){ref-type="table-fn"}              1                                                       1                        
   II                                                        1.206                 (1.113--1.308)          \<0.001   1.118   (1.010--1.238)   0.032
   III                                                       1.855                 (1.715--2.007)          \<0.001   1.597   (1.435--1.777)   \<0.001
   IV                                                        3.090                 (2.840--3.361)          \<0.001   1.905   (1.696--2.139)   \<0.001
  Intake of medication                                                                                                                        
   No[\*](#tfn7-copd-9-203){ref-type="table-fn"}             1                                                       1                        
   Yes                                                       0.817                 (0.763--0.875)          \<0.001   0.559   (0.514--0.609)   \<0.001
  Medicine omission                                                                                                                           
   No[\*](#tfn7-copd-9-203){ref-type="table-fn"}             1                                                       1                        
   Yes                                                       1.055                 (1.002--1.111)          0.043     1.003   (0.939--1.071)   0.927
  Smoking                                                                                                                                     
   Never smoker[\*](#tfn7-copd-9-203){ref-type="table-fn"}   1                                                       1                        
   Ex-smokers                                                1.193                 (1.048--1.358)          0.007     0.846   (0.712--1.004)   0.056
   Light smokers (\<20 pack-years)                           0.959                 (0.829--1.110)          0.576     0.800   (0.661--0.967)   0.021
   Heavy smokers (\>20 pack-years)                           1.144                 (1.010--1.296)          0.034     0.967   (0.817--1.144)   0.694
  Comorbidity (number of diseases)                                                                                                            
   0[\*](#tfn7-copd-9-203){ref-type="table-fn"}              1                                                       1                        
   1                                                         1.046                 (0.958--1.142)          0.317     0.981   (0.880--1.094)   0.736
   2                                                         1.259                 (1.154--1.373)          \<0.001   1.039   (0.929--1.162)   0.500
   3                                                         1.666                 (1.514--1.833)          \<0.001   1.494   (1.321--1.689)   \<0.001
   4+                                                        3.071                 (2.832--3.330)          \<0.001   2.355   (2.102--2.639)   \<0.001

**Note:**

Reference category.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; IRR, incidence rate ratio.
